Brokers Set Expectations for Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for Tourmaline Bio in a research report issued on Sunday, May 4th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.15) per share for the year, up from their prior forecast of ($3.20). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share.

Several other research analysts have also recently weighed in on the company. Chardan Capital reiterated a "buy" rating and set a $70.00 price target on shares of Tourmaline Bio in a research report on Monday. Lifesci Capital started coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They set an "outperform" rating and a $58.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Tourmaline Bio in a report on Monday. Finally, Wedbush raised their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tourmaline Bio currently has an average rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Stock Performance

NASDAQ TRML opened at $14.54 on Wednesday. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79. The firm has a market capitalization of $373.46 million, a P/E ratio of -5.16 and a beta of 2.11. The stock has a 50-day simple moving average of $15.32 and a two-hundred day simple moving average of $18.98.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.02.

Institutional Investors Weigh In On Tourmaline Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in Tourmaline Bio by 283.7% during the third quarter. Barclays PLC now owns 31,833 shares of the company's stock valued at $819,000 after purchasing an additional 23,536 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Tourmaline Bio by 16.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company's stock valued at $381,000 after buying an additional 2,100 shares in the last quarter. Brooklyn Investment Group purchased a new position in Tourmaline Bio in the 4th quarter valued at about $32,000. SG Americas Securities LLC boosted its holdings in Tourmaline Bio by 3.4% in the 4th quarter. SG Americas Securities LLC now owns 34,812 shares of the company's stock worth $706,000 after buying an additional 1,140 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Tourmaline Bio by 2.1% during the 4th quarter. Rhumbline Advisers now owns 35,591 shares of the company's stock worth $722,000 after buying an additional 718 shares in the last quarter. Hedge funds and other institutional investors own 91.89% of the company's stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.